Mundipharma commences COPD trial
Mundipharma Research Limited (Mundipharma) has announced a major milestone in the development programme of flutiform® (fluticasone propionate/formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 19, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Respiratory Source Type: news
fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 7:43:00 PMLast Editorial Review: 7/15/2013 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - July 15, 2013 Category: Respiratory Medicine Source Type: news
fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 7:43:00 PMLast Editorial Review: 7/15/2013 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 15, 2013 Category: Drugs & Pharmacology Source Type: news
Regulatory update: fluticasone furoate/vilanterol submission in Japan
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVARTM ELLIPTATM) in patients with chronic obstructive pulmonary disease (COPD) has been withdrawn from the current Japanese New Drug Application (JNDA) (Source: GSK news)
Source: GSK news - July 12, 2013 Category: Pharmaceuticals Source Type: news
fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)
Title: fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)Category: MedicationsCreated: 6/12/2013 2:48:00 PMLast Editorial Review: 6/12/2013 2:48:05 PM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - June 12, 2013 Category: Respiratory Medicine Source Type: news
fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)
Title: fluticasone furoate and vilanterol inhalation powder (Breo Ellipta)Category: MedicationsCreated: 6/12/2013 2:48:00 PMLast Editorial Review: 6/12/2013 2:48:05 PM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 12, 2013 Category: Drugs & Pharmacology Source Type: news
Breo Ellipta for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) is a dry powder inhaler indicated for the long-term maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease… (Source: Drug Development Technology)
Source: Drug Development Technology - May 26, 2013 Category: Pharmaceuticals Source Type: news
Breo Ellipta (Fluticasone Furoate and Vilanterol Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2013 Category: Drugs & Pharmacology Source Type: news
Aerosolized Swallowed Fluticasone vs Esomeprazole for EoEAerosolized Swallowed Fluticasone vs Esomeprazole for EoE
Are inhaled corticosteroids as effective as proton pump inhibitors in the treatment of eosinophilic esophagitis? The American Journal of Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New Inhaler Drug Approved By FDA For Chronic COPD
The U.S. Food and Drug Administration has just announced the approval of a form of new long-term treatment for patients suffering from chronic obstructive pulmonary disease (COPD). The new treatment is an inhaler drug called Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). It is also approved for the treatment of exacerbations in COPD patients. COPD is a form of lung disease that progressively gets worse, it is characterized by the occurrence of chronic bronchitis or emphysema (a pair of co-existing diseases that narrow the airways)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 12, 2013 Category: Consumer Health News Tags: COPD Source Type: news
FDA Approves 'Son of Advair' for COPD ExacerbationsFDA Approves 'Son of Advair' for COPD Exacerbations
Reformulated fluticasone plus vilanterol in combination reduced exacerbations in clinical trials, but pneumonia risk remains a concern. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease
The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 10, 2013 Category: American Health Source Type: news
FDA Panel Recommends Approval of Once-Daily COPD Treatment FDA Panel Recommends Approval of Once-Daily COPD Treatment
The combination of fluticasone furoate and vilanterol provides a clinically meaningful benefit for long-term maintenance therapy in COPD, an FDA panel has concluded. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Latest Sleep Articles Available from March
Explore the latest sleep articles published in March. You can learn ways to decrease your anxiety and relieve insomnia. Consider how to treat restless legs syndrome (RLS) with iron supplements. Finally discover why you feel so sleepy after lunch (hint: it's not the food). Review a detailed article describing how you can sleep better at night. Expand your understanding of anatomy by learning about adenoids, turbinates, and the nasal septum. Finally, read about the use of Flonase nasal spray to treat your allergies. There is always something new to learn about in the world of sleep!
Read More:
Ways to Decrease Anxiety an...
Source: About Sleep Disorders - March 30, 2013 Category: Sleep Medicine Source Type: news
Horizon scanning: Phase III safety study of once-daily fluticasone furoate plus vilanterol in the treatment of asthma
Source: Thorax
Area: News
The results of a Phase III study evaluating the safety of an investigational combination of fluticasone furoate and vilanterol in the treatment of asthma have been published early online in Thorax.
The authors note that long-acting ?2 agonists (LABA) are recommended in combination with inhaled corticosteroids (ICS) for patients with asthma who remain symptomatic on low-medium dose ICS alone. The ICS fluticasone furoate (FF), together with the LABA vilanterol (VI), are in development as a novel, once-daily ICS/LABA combination inhaler for asthma and chronic obstructive pulmonary disease...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
